Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Common Equity: 2011-2024

Historic Common Equity for Mimedx Group (MDXG) over the last 14 years, with Dec 2024 value amounting to $193.1 million.

  • Mimedx Group's Common Equity rose 32.01% to $238.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.9 million, marking a year-over-year increase of 32.01%. This contributed to the annual value of $193.1 million for FY2024, which is 35.31% up from last year.
  • Mimedx Group's Common Equity amounted to $193.1 million in FY2024, which was up 35.31% from $142.7 million recorded in FY2023.
  • In the past 5 years, Mimedx Group's Common Equity registered a high of $193.1 million during FY2024, and its lowest value of -$18.0 million during FY2022.
  • For the 3-year period, Mimedx Group's Common Equity averaged around $105.9 million, with its median value being $142.7 million (2023).
  • As far as peak fluctuations go, Mimedx Group's Common Equity tumbled by 22,036.59% in 2022, and later spiked by 893.40% in 2023.
  • Over the past 5 years, Mimedx Group's Common Equity (Yearly) stood at -$150,000 in 2020, then soared by 154.67% to $82,000 in 2021, then plummeted by 22,036.59% to -$18.0 million in 2022, then skyrocketed by 893.40% to $142.7 million in 2023, then skyrocketed by 35.31% to $193.1 million in 2024.